Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 32

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 32
---
 we were the first to make the inventions claimed in our owned or licensed patents or pending patent
applications, or that we were the first to file for patent protection of such inventions. Also, an examination is often lengthy and can
involve numerous challenges to the claims sought. As a result, the issuance, scope, validity, enforceability and commercial value of our
patent rights are highly uncertain. Pending and future patent applications may not result in patents being issued which protect our technology
or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes
in either the patent laws or interpretation of the patent laws in the United States, the European Union, and other countries may diminish
the value of the underlying patents under our License Agreement or narrow the scope of our patent protection.

Any inability by us to adequately protect the underlying
intellectual property with respect to proprietary technology and products we plan to develop may have a material adverse effect on our
business, operating results, and financial position.

If we successfully identify new product candidates
and license those rights, we may fail to comply with our obligations under any potential license in which we may license intellectual
property and other rights from third parties or otherwise experience disruptions to our business relationships with our future licensors,
and we could lose those rights or other rights which could be the products upon which our business depends. 

If we fail to comply with our obligations under any
potential future license agreement, including the payment of all amounts due under these potential agreements, we may lose the rights
to developed and potentially commercialize the underlying technology, and the licensor may have the right to terminate the license agreement
or restrict our rights upon notice, in which event we would not be able to develop or market products covered by the agreement, which
could be the products upon which our business depends. For instance, on May 4, 2022, we entered into a License Agreement with CWRU allowing
us to develop and commercialize our former lead product candidate, MIE-101. On March 22, 2024, we received a notice of termination from
CWRU terminating the License Agreement due to our inability to pay amounts owed to CWRU in accrued patent fees due to our limited cash
position.

If we successfully identify new product candidates
and license those rights, we may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could
be expensive, time consuming and unsuccessful. 

Because competition in our